Intradermal vaccine delivery: Will new delivery systems transform vaccine administration?

Vaccine

Volumn 26, Issue 26, 2008, Pages 3197-3208

  Lambert, Paul Henri ^a   Laurent, Philippe E ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b BD Medical Pharmaceutical Systems   (France)

Author keywords

ID injection; Intradermal injection; Vaccine delivery

Indexed keywords

ALUMINUM SALT; BCG VACCINE; CANCER VACCINE; CARBOXYMETHYLCELLULOSE; CHOLERA VACCINE; CPG OLIGODEOXYNUCLEOTIDE; DENGUE VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DNA VACCINE; ESCHERICHIA COLI ENDOTOXIN; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; MEASLES MUMPS RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; POLYLACTIC ACID; RABIES VACCINE; RECOMBINANT HEPATITIS B VACCINE; ROTAVIRUS VACCINE; TETANUS TOXOID; TUMOR CELL VACCINE; TYPHOID VACCINE; UNINDEXED DRUG; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ANTIBODY RESPONSE; CANCER IMMUNIZATION; CHOLERA; DENDRITIC CELL; DENGUE; DIPHTHERIA; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPORATION; EPIDEMIC ENCEPHALITIS; FACIAL NERVE PARALYSIS; HEPATITIS A; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOREACTIVITY; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; INJECTION SITE INDURATION; INJECTION SITE NODULE; INNATE IMMUNITY; IONTOPHORESIS; JET INJECTION; LUNG TUBERCULOSIS; MASS IMMUNIZATION; MEASLES; MELANOMA; MICROINJECTION; MUMPS; NEEDLESTICK INJURY; NONHUMAN; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RABIES; REVIEW; RISK REDUCTION; RUBELLA; SIDE EFFECT; SKIN PIGMENTATION; SKIN STRUCTURE; STRATUM CORNEUM; T LYMPHOCYTE ACTIVATION; TETANUS; TRAVELLER DIARRHEA; TUBERCULIN TEST; TYPHOID FEVER; VACCINATION REACTION; VIRAL CONTAMINATION; YELLOW FEVER;

HUMANS; INJECTIONS, INTRADERMAL; VACCINES;

EID: 44749091856     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.095     Document Type: Review

References (155)

1. Plotkin S.A., and Orenstein W.A. Offit PA vaccines. 5th ed. (2007), Saunder
2. Mantoux C. L'intradermo-réaction a la tuberculine et son interprétation clinique. Presse Medicale 18 (1910) 10-13
3. Bricks L.F. Percutaneous or intradermal BCG vaccine?. J Pediatria 80 (2004) 93-98
4. Briggs D.J., Banzhoff A., Nicolay U., Sirikwin S., Dumavibhat B., Tongswas S., et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull WHO 78 (2000) 693-698
5. http://www.who.int/mediacentre/factsheets/smallpox/en/.
6. Kravitz H. A simplified technique for vaccination against small pox. Pediatrics 27 (1961) 219-226
7. Tuft L. Active immunization against thyphoid fever, with particular reference to an intradermal method. J Lab Clin Med 16 (1931) 552-556
8. Tuft L., Yage E., and Rodgers S. Comparative study of the antibody response after various methods of administration of mixed thyphoide vaccine. J Infect Dis 5 (1932) 95
9. Francis T., and McGill T. The antibody response of human subjects vaccinated with the virus of human influenza. J Exp Med 65 (1937) 251-259
10. Van Gelder D., Greenspan F., and Dufresne N. Influenza vaccination: comparison of intracutaneous and subcutaneous methods. Naval Med Bull 47 (1947) 197-206
11. Weller T.B., Cheever F.S., and Enders J.F. Immunlogic reactions following the intradermal inoculation of influenza A and B vaccine. Proc Soc Exp Biol Med 67 (1948) 96-101
12. Hong Kong Meascles Vaccine Committee. Comparative trial of live attenuated measles vaccine in Hong Kong by intramuscular and intradermal injection. Bull WHO 36 (1967) 375-384
13. Cutts F.T., Clemants C.J., and Bennett J.V. Alternative route of measles immunization: a review. Biologicals 25 (1997) 323-338
14. MacBean A.M., Agle A.N., Compaore P., Foster S.O., and McCormack W.M. Comparison of intradermal and subcutaneous routes of cholera vaccine administration. Lancet 1 (1972) 527-529
15. Nicholson K.G., Prestage H., Cole P.J., Turner G.S., and Bauer S.P. Multsite intradermal antirabies vaccination. Immune response in man and protection of rabbits against death from street virus by postexposure administration of human diploid-cell-strain rabies vaccine. Lancet 2 (1981) 915-918
16. Warrel M.J., Nicholson K.G., Warrell D.A., Suntharasamai P., Chanthavanich P., Viravan C., et al. Economical multiple-site intradermal immunization with human diploid-cell-strain vaccine intradermal immunisationwith human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet 335 (1985) 896-898
17. Miller K.D., Gibbs R.D., Mulligan N.M., Nutman T.B., and Francis D.P. Intradermal hepatitis B virus vaccine: immunogenicity and side effects in adults. Lancet 2 (1983) 1454-1456
18. Goldwater P.N., Woodfield D.G., Ramirez A.M., and Steed I. Intradermal hepatitis B virus vaccination. N Z Med J 99 (1896) 703-705
19. Halsey N.A., Reppert E.J., Margolis H.S., et al. Intradermal hepatitis B vaccination in an abbreviated schedule. Vaccine 4 (1986) 228-232
20. Clarke J.A., Hollinger F.B., Lewis E., Russel L.A., Miller C.H., Huntley A., et al. Intradermal inoculation with hepatavax-B immune response and histologic evaluation of injection sites. JAMA 26 (1989) 2567-2571
21. Connolly J.H., Dirk G.W., and Corkin D.L. Antibody response following intradermal or oral administration of formalinised poliomyelitis. Lancet 2 (1958) 333-336
22. Samuel B.U., Cherian T., Sridharan G., Mukundan P., and John T.J. Immune response to intradermally injected inactivated poliovirus vaccine. Lancet 338 (1991) 343-344
23. Samuel B.U., Cherian M.D., Rajasingh J., Reghupathy P., and John T.J. Immune response of infants to inactivated poliovirus vaccine injected intradermally. Vaccine 10 (1992) 135
24. Nirmal S., Cherian T., Samuel B.U., Rajasingh J., Raghupathy P., and John T.J. Immune response of infants to fractional doses of intradermally administrated inactivated poliovirus vaccine. Vaccine 16 (1998) 928-931
25. Briggs D.J., Banzhoff A., and Nicolay U. Antibody responses of patients alter postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull WHO 78 (2000) 693-698
26. Rivez M., and Peterson J. Intradermal hepatitis B vaccination. Ann Parmacother 25 (1991) 628-633
27. Somboonslip W., Eiam-Ong S., Tungsanga K., and Tirawatanapong T. Immune response of intradermal hepatitis B vaccination at lower dose versus intramuscular vaccination at double standard dose in predialytic chronic renal failure patients. J Med Assoc Thai 86 (2003) 1122-1127
28. Chau K.F., Cheng Y.L., Tsang D.N.C., Choi K.S., Wong K.M., Chak W.L., et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: A comparison with the intramuscular vaccination. Am J Kidney Dis 43 (2004) 910-917
29. Belche R.B., Newman F.K., Wilkins K., Graham I.L., Babusis E., Ewell M., et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25 (2007) 6755-6763
30. McCarroll J.R., and Kilbourne E.D. Immunization with Asian-strain influenza vaccine. N Engl J Med 259 (1958) 618-621
31. Booy R., Weber F., Saville M., and Holland D. Immunogenicity of a novel influenza vaccine delivered by intradermal microinjection in over 60 year-olds. Options for the CONTROL of influenza VI. Toronto, Canada (June 2007) (Abstract)
32. Kanhou H., Sanchez S., Babaie M., Chien C., Hamwi G., Ricaurte J.C., et al. The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in immunodeficiency virus-positive patients. Arch Intern Med 166 (2006) 1417
33. Horowitz M.M., Ershler W.B., MbKinney W.P., and Battiola J. Duration of immunity after B vaccination: efficacy of low dose booster vaccine. Ann Inter Med 108 (1988) 185-189
34. Levine M.M., and Sztein M.B. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol 5 (2004) 460-464
35. Simonsen L., Kane A., Llyod J., Zaffran M., and Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull WHO Suppl. 77 (1999) 789-800
36. Dicko M., Oni A.Q., Ganivet S., Kone S., Pierre L., and Jacquet B. Safety of immunization injections in Africa: not simply a problem of logistics. Bull WHO 78 (2000) 163-169
37. Jacobson R.M., Swan A., Adegbenro A., Ludington S.L., Wollan P.C., and Poland G.A. Making vaccine more acceptable methods to prevent and minimize pain and other common adverse events associated with vaccine. Vaccine 19 (2001) 2418-2427
38. Nor Y., Paz A., Sabo E., and Potasman I. Fear of injections in young adults: prevalence and associations. Am J Trop Med Hyg 68 (2003) 341-344
39. Sullivan V.J., Mikszta J.A., Laurent P., Huang J., and Ford B. Noninvasive delivery technology: respiratory delivery of vaccines. Expert Opin Drug Deliv 3 (2006) 87-95
40. Vajdy M., and O'Hagan D.T. Microparticles for intranasal immunization. Adv Drug Deliv Rev 51 (2001) 127-141
41. Illum L., and Davis S.S. Nasal vaccination: a non-invasive vaccine delivery method that holds great promise for the future. Adv Drug Deliv Rev 51 (2001) 1-3
42. Ekwueme D.U., Weniger B.G., and Chen R.T. Model-based estimates of risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africa. Bull WHO Suppl. 80 (2002) 859-870
43. Moyle P.M., McGeary R.P., Blanfield J.T., and Toth I. Mucosal immunization: adjuvant and delivery systems. Curr Drug Deliv 1 (2004) 385-396
44. Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Weekly Rep 2000;49(RR-5):1-22.
45. Kraisinger M. Update on childhood immunization. Am J Health-Syst Pharm 55 (1998) 563-569
46. Dennehy P.H. Rotavirus vaccines: an overview. Clin Microbiol Rev 21 (2008) 198-208
47. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350 February 26 (2004) 896-903
48. Teunissen M.B., Kapsenberg M.L., and Bos J.D. Langerhans cells and related skin dendritic cells. Skin immune system. second edition (1997), CRC Press LLC
49. Pober J.S., and Cotran R.S. Cytokine and endothelial cell biology. Physiol Rev 76 (1990) 427
50. Hoffmann K., Stücker M., Dirschka T., Dirschka, Görtz S., El-Gammal S., et al. Twenty MHz B-scan sonography for visualization and skin thickness measurement of human skin. J Eur Acad Dermatol Venereol 3 (1994) 302-313
51. Seidenari S., Pagnomi A., Di Nardo A., and Giannetti A. Echographic evaluation with image analysis of normal skin: variations according to age and sex. Skin Pharmacol 7 (1994) 201-209
52. Rigal J.D., Escoffier C., Querleux B., Faivre B., Agache P., and Leveques J.L. Assessment of aging of human skin by in-vivo ultrasonic imaging. J Invest Dermatol 93 (1989) 621-625
53. Fornage B., McGavran M.H., Duvic M., and Waldron Ch.A. Imaging of the skin with 20 MHz. US Radiol 189 (1993) 69-76
54. Laurent A., Mistreta F., Bottigioli D., Dahel K., Goujon C., Nicolas J.F., et al. Ecgographic measurement of skin thickness in adults by high frequency ultrasound to asses the appropriate micro needle length for intradermal delivery of vaccines. Vaccine 25 (2007) 6423-6430
55. Gniadecka M., and Jemec G.B.E. Quantitative evaluation of chronological aging and photoaging in vivo: studies on skin echogenicity and thickness. Br J Dermatol 139 (1998) 815-821
56. Lasagni C., and Seidenari S. Echographic assessment of age dependent variations of skin thickness: a study on 162 subjects. Skin Res Technol 1 (1995) 81-85
57. Seidenari S., Gisuti G., Magnoni C., and Pellicani G. Thickness and echogenicity of the skin in children as assessed by 20-MHz ultrasound. Dermatology 201 (2000) 218-222
58. Tsukahara K., Takema Y., Moriwaki S., Fujimura T., Kitahara T., and Imokawa G. Age-related alterations of echogenicity in Japanese skin. Dermatology 200 (2000) 303-307
59. Groswasser J., Kahn A., Bouche B., Hanquinet S., and Perlmuter N. Needle length and injection technique for efficient intramuscular vaccine delivery in infants and children evaluated through an ultrasonographic determination of subcutaneous and muscle layer thickness. Pediatrics 100 (1997) 400-403
60. Poland G.A., Brud A., Jacobson R.M., McDermott K., Wollan P.C., Brakke D., et al. Determination of deltoid fat pad thickness, implication for needle length in adult immunization. JAMA 277 (1997) 1709-1711
61. Cook J.F., Williamson M., and Pond D. Definition of needle length required for intramuscular deltoid injection in elderly adults: an ultrasound study. Vaccine 24 (2006) 937-940
62. Schwartz T. Skin immunity. Br J Dermatol 149 Suppl. (2003) 2-4
63. Cerio R., Griffiths C.E., Cooper K.D., Nickoloff B.J., and Headington J.T. Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Br J Dermatol 121 (1989) 421-431
64. Langerhans P. Uber die nerven des menschliden haut. Virchows Arch 44 (1868) 325
65. Muzio M., Bosisio D., Polentarutti N., D'amico G., Stoppacciaro A., Mancinelli R., et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 164 (2000) 5998-6004
66. Flacher V., Bouschbacher M., Verronesse E., Massacrier C., Sisirak V., Berthier Vergnes O., et al. Human Langherans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J Immunol 177 (2006) 7959-7967
67. Medzhitov R., and Janeway Jr. C.A. Innate immunity: impact on the adaptative immune response. Curr Opin Immunol 9 (1997) 4
68. Steinbrink K., Sorg C., and Macher E. Low zone tolerance to contact allergens in mice: a functional role of CD8+ T helper type 2 cells. J Exp Med 183 (1996) 759-768
69. Jonuleit H., Schmitt E., Schuler G., Knop J., and Enk A.H. Induction of interleukin 10-producing, non proliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogenic immature dendritic cells. J Exp Med 192 (2000) 1213-1222
70. Wang L.F., Lin J.Y., Hsieh K.H., and Lin R.H. Epicutaneous exposure of protein antigen indices a predominant Th2-like response with high IgE production in mice. J Immunol 156 (1996) 4077-4082
71. Spergel J.M., Mizoguchi E., Brewer J.P., Martin T.R., Bhan A.K., and Geha R.S. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerolized antigen in mice. J Clin Invest 101 (1998) 1614-1622
72. Glenn G.M., Rao M., Matyas G.R., and Alving C.R. Skin immunization made possible by cholera toxin. Nature 391 (1998) 851
73. John M., Bridges E.A., Miller A.O., Calderwood S.B., and Ryan E.T. Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies. Vaccine 20 (2002) 2720-2726
74. Bynoe M.S., Evans J.T., Viret C., and Janeway Jr. C.A. Epicutenous immunization with autoantigenic peptides induces T suppressor cells that prevent experimental allergic encephalomyelitis. Immunity 19 (2003) 317-328
75. Etchart N., Hennino A., Friede M., Dahel K., Dupouy M., Goujon-Henry C., et al. Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans. Vaccine 25 (2007) 6891-6899
76. Kang K., Hammerberg C., Meunier L., and Cooper K.D. CD11b+ macrophage that infiltrate human epidermis after in vivo ultraviolet exposure potently produce IL-10 and represents the major secretary source of epidermal IL-10 protein. J Immunol 153 (1994) 5256-5264
77. Lee H.S., Kooshesh F., Sauder D.N., and Kondo S. Modulation of TGF-β1 production from human keratinocytes by UVB. Exp Dermatol 6 (1997) 105-110
78. Hart P.H., Grimbaldeston M.A., and Finlay-Jones J.J. Mast cells in UVB-induced immunosuppresion. J Photochem Photobiol 55 (2000) 81-87
79. McLoone P., Man I., Yule S., Fluitman A., Van Loveren H., Norval M., et al. Whole body (TL-01) or UVA-1 irradiation dose not alter immunomodulatory cytokines in the serum of human volunteers. Photodermatol Photoimmunol Photomed 20 (2004) 76-80
80. WHO. Who recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. WHO/EMS/ZOO/96.6.
81. Brewer T.F. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 31 Suppl. 3 (2000) 64-67
82. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.Y., et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 271 (1994) 698-702
83. Flynn P.M., Shenep J.L., Mao L., Crawford R., Williams B.F., and Williams B.G. Influence of needle gauge in Mantoux skin testing. Chest 106 (1994) 1463-1465
84. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., and Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351 (2004) 2295-2301
85. Henderson E.A., Louie T.J., Ramotar K., Ledgerwood D., Hope K.M., and Kennedy A. Comparison of higher dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare worker. Infect Control Hosp Epidemiol 21 (2000) 264-269
86. Ghabouli M.J., Sabouri A.H., Shoeibi N., Bajestan S.N., and Baradaran N. High seroprotection rate induced by intradermal administration of a recombinant hepatitis B vaccine in young healthy adults: comparison with standard intramuscular vaccination. Eur J Epidemiol 19 (2004) 871-875
87. Roozbeh J., Moini M., Lankarani K.B., Sagheb M.M., Shahpoori S., and Bastani B. Low dose intradermal versus high dose intramuscular hepatitis B vaccination in patients on chronic hemodialysis. ASAIO J 51 (2005) 242-245
88. Charest A.F., McDougall J., and Goldstein M.B. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 36 (2000) 976-983
89. Rahman F., Dahmen A., Herzoq-Hauff S., Büher W.O., Galle P.R., and Löhr H.F. Cellular and humoral immune response induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hapatology 31 (2000) 521-527
90. Chanchairujira T., Chantaphakul N., Thanwanderdee T., and Ong-Ajwooth L. Efficacy of intradermal hepatitis B vaccination compared to intramuscular vaccination in hemodialysis patients. J Med Assoc Thai 89 Suppl. 2 (2006) S33-S40
91. Birkhaug K. An experimental and clinical investigation of a percutaneous (Rosenthal) method of BCG vaccination. Nord Med 38 (1941) 107-111
92. Griffith A.H. BCG vaccination by multiple puncture. Lancet 273 (1959) 1170-1172
93. Merieux C., Merieux A., and Triau R. Tuberculination, vaccination BCG ou antivariolique à l'aide d'une bague à pointe. Arch Mal Prof 27 (1966) 444-449
94. Research Committee of the British Thoracic and Tuberculosis Association. BCG vaccination by multiplepuncture: fourth report. Tubercle 1971;52:19-30.
95. Canner E.W. Percutaneous multiple puncture method of administering BCG vaccine. Public Health 105 (1991) 405
96. Mori T., Yamauchi Y., and Shiozawa K. Lymph node swelling due to bacilli Calmette-Guerin vaccination with multiple puncture method. Tubercle Lung Dis 77 (1996) 269-273
97. Weniger BG. New high speed jet injectors for mass vaccination: pros and cons of DCJIs versus MUNJIs, WHO initiative for vaccine research: Global Vaccine Research Forum, Montreux, Switzerland; 2004.
98. CDC National Immunization Program. Needle-free injection technology. www.cdc.gov/dev/jetinject.htm (February 25, 2005).
99. Jackson L.A., Austin G., Chen R.T., Stout R., DeStefano F., Gorse G.J., et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle free jet injectors. Vaccine 19 (2001) 4703-4709
100. Hoffman P.N., Abuknesha R.A., Andrews N.J., Samuel D., and Llyod J.S. A model to assess the infection potential of jet injectors used in mass vaccination. Vaccine 19 (2001) 4020-4027
101. Giudice E.L., and Campbell J.D. Needle-free vaccine delivery. Adv Drug Deliv 58 (2006) 68-89
102. Parent du Chatelet I., et al. Clinical immunogenicity and tolerance studies of liquid vaccines delivered by jet-injector and a new single-use cartridge (Imule): comparison with standard syringe injection. Vaccine 15 (1997) 449-458
103. Sarno M.J., Blase E., Galindo R., Ramirez R., Schirmer C.L., and Trujillo-Juarez D.F. Clinical immunogenicity of measles, mumps and rubella vaccine delivered by the Injex jet injector: comparison with standard syringe injection. Pediatr Infect Dis J 75 (2000) 11630-11640
104. Mumper R.J., and Cui Z. Genetic immunization by jet injection of targeted pDMA coated nanoparticles. Methods 31 (2003) 255-266
105. Epstein J.E., Gorak E.J., Charoenvit Y., Wang R., Freydberg N., Osinowo O., et al. Safety, tolerability, and lack of antibody response after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther 13 (2002) 1551-1560
106. Cui Z., and Mumper R.J. Dendritic cell-targeted genetic vaccines engineered from novel microemulsion precursors. Mol Ther 3 (2001) S352
107. Cui Z., Baizer L., and Muper R.J. Intradermal immunization with novel plasmid DNA coated nanoparticles via a needle-free injection device. J Biotechnol 102 (2003) 105-115
108. Babuik S., Baca-Estrada M., Babiuk L.A., Ewen C., and Foldvari M. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Control Release 66 (2000) 199-214
109. Matheï C., Van Damme P., and Mehus A. Hepatitis B vaccine administration comparison between jet gun and syringe and needle. Vaccine 15 (1997) 402-404
110. Williams C.G. Poliomyelitis: extinct by year 2000: but not over. AAOHIN J 48 (2000) 25-31
111. Laurent P.E., Bonnet S., Regolini P., Alchas P., Mikszta J.A., Pettis R., et al. Evaluation of the clinical performance of new intradermal vaccine administration technique and associated delivery system. Vaccine 25 (2007) 8833-8842
112. Belshe R.B., Newman F.K., Cannon J., Duane C., Trenor J., Van Hoecke C., et al. Serum antibody response after intradermal vaccination against influenza. N Eng J Med 351 (2004) 2286-2294
113. Mikszta J.A., Sullivan V.J., Dean C., Waterston A.M., Alarcon J.B., Dekker J.P., et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J Infect Dis 191 (2005) 278-288
114. Mikszta J.A., Dekker J.P., Harvey N.G., Dean C.H., Brittingham J.M., Huang J., et al. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect Immun 74 (2006) 6806-6810
115. Dean C.H., Alarcon J.B., Waterston A.M., Draper K., Early R., Guirakhoo F., et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese Encephalitis (ChimeriVax-JE) in non-human primates. Hum Vac 1 (2005) 6-11
116. Glenn G., and Kenny R.T. Transcutaneous immunization. In: Levine M.M., Kaêr J.B., Rappuoli R., Liu M.A., and Good M.F. (Eds). New generation vaccines (2004), Marcel Dekker, New York, NY 401-412
117. Hammond S.A., Guebre-Xabier M., Yu J., and Glenn G.M. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. Crit Rev Ther Drug Carrier Syst 18 (2001) 503-526
118. Godefroy S., Peyre M., Garcia N., Muller S., Sesardic D., and Partidos C.D. Effect of skin barrier disruption on immune response to topically applied cross-reacting material, CRM (197), of diphtheria toxin. Infect Immun 73 (2005) 4803-4809
119. Peachman K.K., Mangala R., and Alving C.R. Immunization with DNA through the skin. Methods 31 (2003) 232-242
120. Glenn G.M., Kenney R.T., Ellingsworth L.R., Frech S.A., Hammond S.A., and Zoeteweij J.P. Transcutaneous immunization and immunostimulation strategies: capitalizing on the immunocompetence of the skin. Expert Rev Vac 2 (2003) 253-267
121. Gupta P.N., Mishra V., Rawat A., Dubey P., Mahor S., Jain S., et al. Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. Int J Pharm 293 (2005) 73-82
122. Banga A.K., and Prausnitz M.R. Assessing the potential of skin electroporation for the delivery of protein and gene based drugs. Trend Biotechnol 16 (1998) 408-412
123. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M., et al. Increased vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164 (2000) 4635-4640
124. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchaud V., et al. Effect of plasmid DNA vaccine design and in-vivo electroporation on the resulting vaccine-specific immune response in rhesus macaques. J Virol 81 (2007) 5257-5269
125. Hooper J.W., Golden J.W., Ferro A.M., and King A.D. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 25 (2007) 1814-1823
126. Pan H., Zhou Y., Sieling F., Shi J., Cui J., and Deng C. Sonoporation of cells and gene delivery. Conf Proc IEEE Eng Med Biol Soc 5 (2004) 3531-3534
127. Lee S., McAuliffe D.J., Flotte T.J., Kollias N., and Doukas A.G. Photomechanical transcutaneous delivery of macromolecules. J Invest Dermatol 111 (1998) 925-929
128. Tezel A., Sens A., and Mitragotri S. Frenquency dependence of sonophoresis. Pharm Res 18 (2001) 1694-1700
129. Tezel A., Sens A., and Migtragotri S. Description of transdermal transport of hydrophilic solutes during low-frequency sonophoresis based on modified porous pathway model. J Pharm Sci 92 (2003) 381-393
130. Tezel A., Paliwal S., Shen Z., and Mitragotri S. Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 23 (2005) 3800-3807
131. Menon G.K., Kollias N., and Doukas A.G. Ultrascruture evidence of stratum corneum permeabilization induced by photomechanical wave. J Invest Dermatol 121 (2003) 104-109
132. Lees S., McAuliffe D.J., Flotte T.J., Kullias N., and Doukas A.G. Photomechanical transdermal delivery: the effect of laser confinement. Lasers Surg Med 28 (2001) 344-347
133. Prausnitz M.R. Microneedles for transdermal drug delivery. Adv Drug Deliv 56 (2004) 581-587 (Review)
134. Park J.H., Allen M.G., and Prausnitz M.R. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J Control Release 104 (2005) 51-66
135. Henry S., McAllister D.V., Allen M.G., and Prausnitz M.R. Microfabricated microneedles: a novel approach to transdermal drug delivery. J Pharm Sci 87 (1998) 922-925
136. McAllister D.V., Wang P.M., Davis S.P., Park J.H., Canatella P.J., Allen M.G., et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Acad Sci USA 100 (2003) 13755-13760
137. Martanto W., Davis S.P., Holiday N.R., Wang J., Gill H.S., and Prausnitz M.R. Transdermal delivery of insulin using microneedle in vivo. Pharm Res 21 (2004) 947-952
138. Mikszta J.A., Alarcon J.B., Brittingham J.M., Sutter D.E., Pettis R.J., and Harvey N.G. Improved genetic immunization via micromechanical disruption of skin barrier function and targeted epidermal delivery. Nat Med 8 (2002) 415-419
139. Cormier M., and Daddona P.E. Macroflux technology for transdermal delivery of therapeutic proteins and vaccines. In: Rathbone M.J., Hadgraft J., and Roberts M.S. (Eds). Modified release drug delivery technology (2002), New York/Basel, Marcel Dekker 589-598
140. Matriano J., Cormier M., Johnson B., Young W., Buttery M., Nyam K., et al. Macroflux microneedle array patch technology: a new and efficient approach for intracutaneous immunization. Pharm Res 19 (2002) 63-70
141. Cormier M., Johnson B., Ameri M., Nyam K., Librian L., Zhang D.D., et al. Transdermal delivery of desmopressin using coated microneedle array patch. J Control Release 97 (2004) 503-511
142. Park J.H., Allen M.G., and Prausnitz M.R. Polymer microneedles for controlled-release drug delivery. Pharm Res 23 (2006) 106-111
143. Schijus V.E. Induction and direction of immune response but vaccine adjuvants. Crit Rev Immunol 21 (2001) 75-85
144. Lindblad E.B. Aluminium adjuvants: in retrospect and prospect. Vaccine 22 (2004) 3658-3668
145. Li H., Nookala S., and Re F. Aluminium hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 178 (2007) 5271-5276
146. Carisson U., Brudin L., Eliason I., and Hansson B.G. Hepatitis A vaccination by intracutaneous low dose administration: a less expensive alternative. Scand J Infect Dis 28 (1996) 4358
147. Brindle R.J., Morris C.A., Berger R., and Kurtz J.B. Inadequate response to intradermal hepatitis A vaccine. Vaccine 12 (1994) 483-484
148. Bertinetti C., Zirlik K., Heining-Mikesch K., Ihorst G., Dierbach H., Waller C.F., et al. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune response despite profound immunosuppression. Cancer Res 66 (2006) 4496-4502
149. Morita S., Oka Y., Tsuboi A., Kawakami M., Maruno M., Izumoto S., et al. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on phase I data. Jpn J Clin Oncol 36 (2006) 231-236
150. Zoeteweij J.P., Epperson D.E., Porter J.D., Zhang C.X., Frolova O.Y., Constantinides A.P., et al. GM1 binding-deficient exotoxin is a potent non inflammatory broad spectrum intradermal immunoadjuvant. J Immunol 177 (2006) 1197-1207
151. Davis H.L., Weeratna R., Waldshmidt T.J., Tygrett L., Schorr J., and Krieg A.M. J Immunol 160 (1998) 870-876
152. Benoit M.A., Ribet C., Distexhe J., Hermand D., Letesson J.J., Vandenhaute J., et al. Studies on the potential of microparticles entrapping pDNA-poly(aminoacids) complexes as vaccine delivery systems. J Drug Target 9 (2001) 253-266
153. O'Hagan D.T. Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord 1 (2001) 273-286
154. Lin J.H., Weng C.N., Liao C.W., Yeh K.S., and Pan M.J. Protective effects of oral microencapsulated mycoplasma hyponeumoniae vaccine prepared by co-spray drying method. J Vet Med Sci 65 (2003) 69-74
155. Puri N., Weyand E.H., Abdel-Rahman S.M., and Sinko P.J. An investigation of the intradermal route as an effective means of immunization for microparticulate vaccine delivery systems. Vaccine 18 (2000) 2600-2612